社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
庄棋铭
~经济独立，启发明智~
IP属地：0
+关注
帖子 · 138
帖子 · 138
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
庄棋铭
庄棋铭
·
11-06
$辉瑞(PFE)$
你需要时间和机会
看
161
回复
评论
点赞
2
编组 21备份 2
分享
举报
庄棋铭
庄棋铭
·
11-06
$辉瑞(PFE)$
被低估的企业，加油
看
529
回复
评论
点赞
2
编组 21备份 2
分享
举报
庄棋铭
庄棋铭
·
10-20
加油，你行的。
辉瑞研发开放创新中心在浦东揭幕
人民财讯10月20日电，据浦东发布消息，10月20日下午，辉瑞在浦东揭幕辉瑞研发开放创新中心。辉瑞研发开放创新中心是一个致力于推动中国生物医药行业创新和研发的综合性平台。该中心依托辉瑞北京、上海两地研发中心的资源优势，为中国本土高校、创新生物技术企业、医院及临床研究机构提供能力建设与资源支持。
辉瑞研发开放创新中心在浦东揭幕
看
357
回复
评论
点赞
1
编组 21备份 2
分享
举报
庄棋铭
庄棋铭
·
10-20
$辉瑞(PFE)$
这么有远见的企业，必须买。
看
763
回复
评论
点赞
1
编组 21备份 2
分享
举报
庄棋铭
庄棋铭
·
10-20
有远见的企业。
辉瑞研发开放创新中心在浦东揭幕
人民财讯10月20日电，据浦东发布消息，10月20日下午，辉瑞在浦东揭幕辉瑞研发开放创新中心。辉瑞研发开放创新中心是一个致力于推动中国生物医药行业创新和研发的综合性平台。该中心依托辉瑞北京、上海两地研发中心的资源优势，为中国本土高校、创新生物技术企业、医院及临床研究机构提供能力建设与资源支持。
辉瑞研发开放创新中心在浦东揭幕
看
469
回复
评论
点赞
1
编组 21备份 2
分享
举报
庄棋铭
庄棋铭
·
10-16
这才是🈶远见的好商人。
富国银行、辉瑞CEO警告美国正面临失去全球竞争优势的风险
富国银行首席执行官Charlie Scharf与辉瑞首席执行官Albert Bourla周三在华盛顿出席论坛时警告，虽然美国在多个领域仍具领导地位，但政策不稳与投资不足正，美国正面临失去全球竞争优势的
富国银行、辉瑞CEO警告美国正面临失去全球竞争优势的风险
看
347
回复
评论
点赞
1
编组 21备份 2
分享
举报
庄棋铭
庄棋铭
·
10-15
还有眼光和见识的CEO。
辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作
智通财经APP获悉，辉瑞首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。此番表态正值美国总统特朗普对主要经济竞争对手中国实施一系列关税措施之际。美国众议院去年也曾通过法案试图限制美国企业与中国药企合作。今年初，辉瑞与中国三生制药达成协议，以12.5亿美元预付款加最高48亿美元里程碑付款的条件，获得一款实验性癌症疗法的授权。
辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作
看
259
回复
评论
点赞
2
编组 21备份 2
分享
举报
庄棋铭
庄棋铭
·
10-10
$辉瑞(PFE)$
加油，我们看好你哦
看
723
回复
评论
点赞
1
编组 21备份 2
分享
举报
庄棋铭
庄棋铭
·
10-03
$辉瑞(PFE)$
时间是把杀猪刀，价值回归需要和市场情绪的释放。
看
689
回复
评论
点赞
1
编组 21备份 2
分享
举报
庄棋铭
庄棋铭
·
10-03
$辉瑞(PFE)$
时间是把杀猪刀，需要时间来凑
看
426
回复
评论
点赞
1
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3447258680782140","uuid":"3447258680782140","gmtCreate":1484164662508,"gmtModify":1763296517224,"name":"庄棋铭","pinyin":"zqmzhuangqiming","introduction":"","introductionEn":"","signature":"~经济独立，启发明智~","avatar":"https://static.tigerbbs.com/1cdc53929b69f8b806e35f1372121ca4","hat":"https://static.tigerbbs.com/e6295840391b9cdc17115677ba51429c","hatId":"tiger_head_frame","hatName":"小虎头像框","vip":1,"status":2,"fanSize":10,"headSize":43,"tweetSize":138,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.34%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.45%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":8,"crmLevelSwitch":0,"location":"0","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":7,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":497322792755920,"gmtCreate":1762439486612,"gmtModify":1762439488337,"author":{"id":"3447258680782140","authorId":"3447258680782140","name":"庄棋铭","avatar":"https://static.tigerbbs.com/1cdc53929b69f8b806e35f1372121ca4","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3447258680782140","authorIdStr":"3447258680782140"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$ </a><v-v data-views=\"1\"></v-v> 你需要时间和机会","listText":"<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$ </a><v-v data-views=\"1\"></v-v> 你需要时间和机会","text":"$辉瑞(PFE)$ 你需要时间和机会","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/497322792755920","isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":497320619848240,"gmtCreate":1762439466996,"gmtModify":1762439468746,"author":{"id":"3447258680782140","authorId":"3447258680782140","name":"庄棋铭","avatar":"https://static.tigerbbs.com/1cdc53929b69f8b806e35f1372121ca4","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3447258680782140","authorIdStr":"3447258680782140"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$ </a><v-v data-views=\"1\"></v-v> 被低估的企业，加油","listText":"<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$ </a><v-v data-views=\"1\"></v-v> 被低估的企业，加油","text":"$辉瑞(PFE)$ 被低估的企业，加油","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/497320619848240","isVote":1,"tweetType":1,"viewCount":529,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":491317209677896,"gmtCreate":1760971643235,"gmtModify":1760971646487,"author":{"id":"3447258680782140","authorId":"3447258680782140","name":"庄棋铭","avatar":"https://static.tigerbbs.com/1cdc53929b69f8b806e35f1372121ca4","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3447258680782140","authorIdStr":"3447258680782140"},"themes":[],"htmlText":"加油，你行的。","listText":"加油，你行的。","text":"加油，你行的。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/491317209677896","repostId":"2576859046","repostType":2,"repost":{"id":"2576859046","kind":"news","pubTimestamp":1760961641,"share":"https://www.laohu8.com/m/news/2576859046?lang=&edition=full","pubTime":"2025-10-20 20:00","market":"hk","language":"zh","title":"辉瑞研发开放创新中心在浦东揭幕","url":"https://stock-news.laohu8.com/highlight/detail?id=2576859046","media":"人民财讯","summary":"人民财讯10月20日电，据浦东发布消息，10月20日下午，辉瑞在浦东揭幕辉瑞研发开放创新中心。辉瑞研发开放创新中心是一个致力于推动中国生物医药行业创新和研发的综合性平台。该中心依托辉瑞北京、上海两地研发中心的资源优势，为中国本土高校、创新生物技术企业、医院及临床研究机构提供能力建设与资源支持。","content":"<html><body><div>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=106.PFE&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1\" width=\"578\"/></p><p> 人民财讯10月20日电，据浦东发布消息，10月20日下午，<span><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></span><span></span>在浦东揭幕<span href=\"http://quote.eastmoney.com/unify/r/106.PFE\" target=\"_blank\" web=\"1\">辉瑞</span>研发开放创新中心。<span href=\"http://quote.eastmoney.com/unify/r/106.PFE\" target=\"_blank\" web=\"1\">辉瑞</span>研发开放创新中心是一个致力于推动中国生物医药行业创新和研发的综合性平台。该中心依托辉瑞北京、上海两地研发中心的资源优势，为中国本土高校、创新生物技术企业、医院及临床研究机构提供能力建设与资源支持。 </p><p>（文章来源：人民财讯）</p> </div></body></html>","source":"stock_eastmoney","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞研发开放创新中心在浦东揭幕</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞研发开放创新中心在浦东揭幕\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-20 20:00 北京时间 <a href=http://finance.eastmoney.com/a/202510203538952896.html><strong>人民财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>人民财讯10月20日电，据浦东发布消息，10月20日下午，辉瑞在浦东揭幕辉瑞研发开放创新中心。辉瑞研发开放创新中心是一个致力于推动中国生物医药行业创新和研发的综合性平台。该中心依托辉瑞北京、上海两地研发中心的资源优势，为中国本土高校、创新生物技术企业、医院及临床研究机构提供能力建设与资源支持。 （文章来源：人民财讯）</p>\n\n<a href=\"http://finance.eastmoney.com/a/202510203538952896.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4599":"减肥药","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0058720904.USD":"联博国际健康护理基金A","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","PFE":"辉瑞","BK4592":"伊斯兰概念","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4588":"碎股","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","BK4007":"制药","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4581":"高盛持仓"},"source_url":"http://finance.eastmoney.com/a/202510203538952896.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2576859046","content_text":"人民财讯10月20日电，据浦东发布消息，10月20日下午，辉瑞在浦东揭幕辉瑞研发开放创新中心。辉瑞研发开放创新中心是一个致力于推动中国生物医药行业创新和研发的综合性平台。该中心依托辉瑞北京、上海两地研发中心的资源优势，为中国本土高校、创新生物技术企业、医院及临床研究机构提供能力建设与资源支持。 （文章来源：人民财讯）","news_type":1,"symbols_score_info":{"PFE":1.5}},"isVote":1,"tweetType":1,"viewCount":357,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":491317241709376,"gmtCreate":1760971610497,"gmtModify":1760971613691,"author":{"id":"3447258680782140","authorId":"3447258680782140","name":"庄棋铭","avatar":"https://static.tigerbbs.com/1cdc53929b69f8b806e35f1372121ca4","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3447258680782140","authorIdStr":"3447258680782140"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$ </a><v-v data-views=\"1\"></v-v> 这么有远见的企业，必须买。","listText":"<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$ </a><v-v data-views=\"1\"></v-v> 这么有远见的企业，必须买。","text":"$辉瑞(PFE)$ 这么有远见的企业，必须买。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/491317241709376","isVote":1,"tweetType":1,"viewCount":763,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":491318477410496,"gmtCreate":1760971566161,"gmtModify":1760971570896,"author":{"id":"3447258680782140","authorId":"3447258680782140","name":"庄棋铭","avatar":"https://static.tigerbbs.com/1cdc53929b69f8b806e35f1372121ca4","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3447258680782140","authorIdStr":"3447258680782140"},"themes":[],"htmlText":"有远见的企业。","listText":"有远见的企业。","text":"有远见的企业。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/491318477410496","repostId":"2576859046","repostType":2,"repost":{"id":"2576859046","kind":"news","pubTimestamp":1760961641,"share":"https://www.laohu8.com/m/news/2576859046?lang=&edition=full","pubTime":"2025-10-20 20:00","market":"hk","language":"zh","title":"辉瑞研发开放创新中心在浦东揭幕","url":"https://stock-news.laohu8.com/highlight/detail?id=2576859046","media":"人民财讯","summary":"人民财讯10月20日电，据浦东发布消息，10月20日下午，辉瑞在浦东揭幕辉瑞研发开放创新中心。辉瑞研发开放创新中心是一个致力于推动中国生物医药行业创新和研发的综合性平台。该中心依托辉瑞北京、上海两地研发中心的资源优势，为中国本土高校、创新生物技术企业、医院及临床研究机构提供能力建设与资源支持。","content":"<html><body><div>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=106.PFE&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1\" width=\"578\"/></p><p> 人民财讯10月20日电，据浦东发布消息，10月20日下午，<span><a href=\"https://laohu8.com/S/PFE\">辉瑞</a></span><span></span>在浦东揭幕<span href=\"http://quote.eastmoney.com/unify/r/106.PFE\" target=\"_blank\" web=\"1\">辉瑞</span>研发开放创新中心。<span href=\"http://quote.eastmoney.com/unify/r/106.PFE\" target=\"_blank\" web=\"1\">辉瑞</span>研发开放创新中心是一个致力于推动中国生物医药行业创新和研发的综合性平台。该中心依托辉瑞北京、上海两地研发中心的资源优势，为中国本土高校、创新生物技术企业、医院及临床研究机构提供能力建设与资源支持。 </p><p>（文章来源：人民财讯）</p> </div></body></html>","source":"stock_eastmoney","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞研发开放创新中心在浦东揭幕</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞研发开放创新中心在浦东揭幕\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-20 20:00 北京时间 <a href=http://finance.eastmoney.com/a/202510203538952896.html><strong>人民财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>人民财讯10月20日电，据浦东发布消息，10月20日下午，辉瑞在浦东揭幕辉瑞研发开放创新中心。辉瑞研发开放创新中心是一个致力于推动中国生物医药行业创新和研发的综合性平台。该中心依托辉瑞北京、上海两地研发中心的资源优势，为中国本土高校、创新生物技术企业、医院及临床研究机构提供能力建设与资源支持。 （文章来源：人民财讯）</p>\n\n<a href=\"http://finance.eastmoney.com/a/202510203538952896.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4599":"减肥药","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0058720904.USD":"联博国际健康护理基金A","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","PFE":"辉瑞","BK4592":"伊斯兰概念","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4588":"碎股","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","BK4007":"制药","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4581":"高盛持仓"},"source_url":"http://finance.eastmoney.com/a/202510203538952896.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2576859046","content_text":"人民财讯10月20日电，据浦东发布消息，10月20日下午，辉瑞在浦东揭幕辉瑞研发开放创新中心。辉瑞研发开放创新中心是一个致力于推动中国生物医药行业创新和研发的综合性平台。该中心依托辉瑞北京、上海两地研发中心的资源优势，为中国本土高校、创新生物技术企业、医院及临床研究机构提供能力建设与资源支持。 （文章来源：人民财讯）","news_type":1,"symbols_score_info":{"PFE":1.5}},"isVote":1,"tweetType":1,"viewCount":469,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":489795889311952,"gmtCreate":1760606212080,"gmtModify":1760606214592,"author":{"id":"3447258680782140","authorId":"3447258680782140","name":"庄棋铭","avatar":"https://static.tigerbbs.com/1cdc53929b69f8b806e35f1372121ca4","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3447258680782140","authorIdStr":"3447258680782140"},"themes":[],"htmlText":"这才是🈶远见的好商人。","listText":"这才是🈶远见的好商人。","text":"这才是🈶远见的好商人。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/489795889311952","repostId":"2575762524","repostType":2,"repost":{"id":"2575762524","kind":"live","pubTimestamp":1760580668,"share":"https://www.laohu8.com/m/news/2575762524?lang=&edition=full","pubTime":"2025-10-16 10:11","market":"nz","language":"zh","title":"富国银行、辉瑞CEO警告美国正面临失去全球竞争优势的风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2575762524","media":"格隆汇","summary":"富国银行首席执行官Charlie Scharf与辉瑞首席执行官Albert Bourla周三在华盛顿出席论坛时警告，虽然美国在多个领域仍具领导地位，但政策不稳与投资不足正，美国正面临失去全球竞争优势的","content":"<html><body><p>富国银行首席执行官Charlie Scharf与辉瑞首席执行官Albert Bourla周三在华盛顿出席论坛时警告，虽然美国在多个领域仍具领导地位，但政策不稳与投资不足正，美国正面临失去全球竞争优势的风险，但人工智能或可成为维持领先地位的关键。Scharf表示，公司开发人员因AI生产效率提升20%至40%，虽然没有裁员，但AI令能完成更多工作。他又预期金融业将面临重大监管变革，包括资本及流动性要求的调整。Bourla呼吁，美国应专注于提升自身创新及生产力，而非单纯遏制中国发展，并称AI将成为医药研发的下一个发展。</p></body></html>","source":"live_gelonghui","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>富国银行、辉瑞CEO警告美国正面临失去全球竞争优势的风险</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n富国银行、辉瑞CEO警告美国正面临失去全球竞争优势的风险\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-16 10:11 北京时间 <a href=https://www.gelonghui.com/rss/live/live.xml><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>富国银行首席执行官Charlie Scharf与辉瑞首席执行官Albert Bourla周三在华盛顿出席论坛时警告，虽然美国在多个领域仍具领导地位，但政策不稳与投资不足正，美国正面临失去全球竞争优势的风险，但人工智能或可成为维持领先地位的关键。Scharf表示，公司开发人员因AI生产效率提升20%至40%，虽然没有裁员，但AI令能完成更多工作。他又预期金融业将面临重大监管变革，包括资本及流动性要求...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0251142724.SGD":"Fidelity America A-SGD","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","PFE":"辉瑞","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4550":"红杉资本持仓","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4588":"碎股","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","SG9999002232.USD":"Allianz Global High Payout USD","LU0971096721.USD":"富达环球金融服务 A","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","WFC":"富国银行","BK4581":"高盛持仓","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4599":"减肥药","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC"},"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_english":false,"share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","article_id":"2575762524","content_text":"富国银行首席执行官Charlie Scharf与辉瑞首席执行官Albert Bourla周三在华盛顿出席论坛时警告，虽然美国在多个领域仍具领导地位，但政策不稳与投资不足正，美国正面临失去全球竞争优势的风险，但人工智能或可成为维持领先地位的关键。Scharf表示，公司开发人员因AI生产效率提升20%至40%，虽然没有裁员，但AI令能完成更多工作。他又预期金融业将面临重大监管变革，包括资本及流动性要求的调整。Bourla呼吁，美国应专注于提升自身创新及生产力，而非单纯遏制中国发展，并称AI将成为医药研发的下一个发展。","news_type":1,"symbols_score_info":{"PFE":1.5,"WFC":1.5}},"isVote":1,"tweetType":1,"viewCount":347,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":489477155615168,"gmtCreate":1760528839503,"gmtModify":1760528841706,"author":{"id":"3447258680782140","authorId":"3447258680782140","name":"庄棋铭","avatar":"https://static.tigerbbs.com/1cdc53929b69f8b806e35f1372121ca4","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3447258680782140","authorIdStr":"3447258680782140"},"themes":[],"htmlText":"还有眼光和见识的CEO。","listText":"还有眼光和见识的CEO。","text":"还有眼光和见识的CEO。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/489477155615168","repostId":"2575513203","repostType":2,"repost":{"id":"2575513203","kind":"news","pubTimestamp":1760511620,"share":"https://www.laohu8.com/m/news/2575513203?lang=&edition=full","pubTime":"2025-10-15 15:00","market":"hk","language":"zh","title":"辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2575513203","media":"智通财经","summary":"智通财经APP获悉，辉瑞首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。此番表态正值美国总统特朗普对主要经济竞争对手中国实施一系列关税措施之际。美国众议院去年也曾通过法案试图限制美国企业与中国药企合作。今年初，辉瑞与中国三生制药达成协议，以12.5亿美元预付款加最高48亿美元里程碑付款的条件，获得一款实验性癌症疗法的授权。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE.US)首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。过去十年间，中国凭借高效的研发流程使其在全球药物研发中的占比跃升至30%。</p><p>布尔拉在纽约出席美中关系全国委员会晚宴时指出：\"在生物制药领域，中国惊人的速度、成本和规模优势已引发全球竞争格局转变。\"他透露，中国目前拥有约1200种新药候选药物，而十年前这一数字仅为60种。</p><p>此番表态正值美国总统特朗普对主要经济竞争对手中国实施一系列关税措施之际。这些针对<a href=\"https://laohu8.com/S/SBAY\">数百亿</a>美元进口商品的关税政策，据称旨在缩小巨额贸易逆差、重振制造业并打击芬太尼贸易。</p><p>美国众议院去年也曾通过法案试图限制美国企业与中国药企合作。该法案最终未获参议院通过，但今年早些时候已有新版本被重新提交。</p><p>尽管中美存在贸易摩擦，欧美制药公司仍寄望中国补充其药物研发管线。今年初，辉瑞与中国<a href=\"https://laohu8.com/S/01530\">三生制药</a>达成协议，以12.5亿美元预付款加最高48亿美元里程碑付款的条件，获得一款实验性癌症疗法的授权。</p><p>布尔拉强调：\"中国生物科技公司去年占大型药企药物授权交易总量的近三分之一，这是创新来源地的重大转变。\"他补充称，<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>企业招募临床试验患者的效率可达美国同行的2至5倍。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-15 15:00 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/1355242.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，辉瑞(PFE.US)首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。过去十年间，中国凭借高效的研发流程使其在全球药物研发中的占比跃升至30%。布尔拉在纽约出席美中关系全国委员会晚宴时指出：\"在生物制药领域，中国惊人的速度、成本和规模优势已引发全球竞争格局转变。\"他透露，中国目前拥有约1200种新药候选药物，而十年前这一数字仅为60种。此番表态正值美国总统...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1355242.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4007":"制药","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","PFE":"辉瑞","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4550":"红杉资本持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY \"A\" (USD) ACC","BK4581":"高盛持仓","BK4588":"碎股","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4568":"美国抗疫概念","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4592":"伊斯兰概念","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","SG9999001176.USD":"United Global Healthcare Acc USD","BK4534":"瑞士信贷持仓","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4585":"ETF&股票定投概念","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","BK4599":"减肥药","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H"},"source_url":"http://www.zhitongcaijing.com/content/detail/1355242.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2575513203","content_text":"智通财经APP获悉，辉瑞(PFE.US)首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。过去十年间，中国凭借高效的研发流程使其在全球药物研发中的占比跃升至30%。布尔拉在纽约出席美中关系全国委员会晚宴时指出：\"在生物制药领域，中国惊人的速度、成本和规模优势已引发全球竞争格局转变。\"他透露，中国目前拥有约1200种新药候选药物，而十年前这一数字仅为60种。此番表态正值美国总统特朗普对主要经济竞争对手中国实施一系列关税措施之际。这些针对数百亿美元进口商品的关税政策，据称旨在缩小巨额贸易逆差、重振制造业并打击芬太尼贸易。美国众议院去年也曾通过法案试图限制美国企业与中国药企合作。该法案最终未获参议院通过，但今年早些时候已有新版本被重新提交。尽管中美存在贸易摩擦，欧美制药公司仍寄望中国补充其药物研发管线。今年初，辉瑞与中国三生制药达成协议，以12.5亿美元预付款加最高48亿美元里程碑付款的条件，获得一款实验性癌症疗法的授权。布尔拉强调：\"中国生物科技公司去年占大型药企药物授权交易总量的近三分之一，这是创新来源地的重大转变。\"他补充称，中国生物制药企业招募临床试验患者的效率可达美国同行的2至5倍。","news_type":1,"symbols_score_info":{"PFE":1.5}},"isVote":1,"tweetType":1,"viewCount":259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":487468910457560,"gmtCreate":1760040016073,"gmtModify":1760040017854,"author":{"id":"3447258680782140","authorId":"3447258680782140","name":"庄棋铭","avatar":"https://static.tigerbbs.com/1cdc53929b69f8b806e35f1372121ca4","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3447258680782140","authorIdStr":"3447258680782140"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$ </a><v-v data-views=\"1\"></v-v> 加油，我们看好你哦","listText":"<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$ </a><v-v data-views=\"1\"></v-v> 加油，我们看好你哦","text":"$辉瑞(PFE)$ 加油，我们看好你哦","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/487468910457560","isVote":1,"tweetType":1,"viewCount":723,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":485256602292760,"gmtCreate":1759499964795,"gmtModify":1759499966502,"author":{"id":"3447258680782140","authorId":"3447258680782140","name":"庄棋铭","avatar":"https://static.tigerbbs.com/1cdc53929b69f8b806e35f1372121ca4","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3447258680782140","authorIdStr":"3447258680782140"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$ </a><v-v data-views=\"1\"></v-v> 时间是把杀猪刀，价值回归需要和市场情绪的释放。","listText":"<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$ </a><v-v data-views=\"1\"></v-v> 时间是把杀猪刀，价值回归需要和市场情绪的释放。","text":"$辉瑞(PFE)$ 时间是把杀猪刀，价值回归需要和市场情绪的释放。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/485256602292760","isVote":1,"tweetType":1,"viewCount":689,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":485256594837568,"gmtCreate":1759499912916,"gmtModify":1759503164007,"author":{"id":"3447258680782140","authorId":"3447258680782140","name":"庄棋铭","avatar":"https://static.tigerbbs.com/1cdc53929b69f8b806e35f1372121ca4","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3447258680782140","authorIdStr":"3447258680782140"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$ </a><v-v data-views=\"1\"></v-v> 时间是把杀猪刀，需要时间来凑","listText":"<a href=\"https://laohu8.com/S/PFE\">$辉瑞(PFE)$ </a><v-v data-views=\"1\"></v-v> 时间是把杀猪刀，需要时间来凑","text":"$辉瑞(PFE)$ 时间是把杀猪刀，需要时间来凑","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/485256594837568","isVote":1,"tweetType":1,"viewCount":426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}